Josh Mandel-Brehm

Josh Mandel-Brehm leads CAMP4 Therapeutics, where he builds a platform using antisense oligonucleotides to target regulatory RNAs and increase gene expression. He is also a founder and board member of Vico Therapeutics. Previously, he worked in business development at Biogen and was an entrepreneur partner at Polaris Partners.

Career